ArticleBMC cancer2026
Prognostic value of systemic immune-inflammation index and prognostic nutritional index in advanced prostate cancer: development and validation of a comprehensive nomogram.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) have emerged as potential prognostic markers in various malignancies, but their combined and interactive value in advanced prostate cancer (PCa) remains underexplored.
methodsThis retrospective cohort study included 115 patients with advanced PCa (American Joint Committee on Cancer(AJCC) stage III–IV) diagnosed between January 2016 and December 2020. SII and PNI were calculated from pretreatment blood samples. Restricted cubic spline (RCS) analysis was used to explore nonlinear relationships. Cox regression identified independent prognostic factors. A nomogram incorporating AJCC stage, SII, and PNI was developed to predict 1-, 3-, and 5-year overall survival (OS). The model was internally validated via bootstrapping, with calibration and decision curve analysis (DCA) assessing accuracy and clinical utility.
resultsWith a median follow-up of 54 months, SII and PNI predicted OS with AUCs of 0.712 and 0.803, respectively. RCS analysis revealed nonlinear, J-shaped (SII) and reverse S-shaped (PNI) relationships with OS and progression-free survival (PFS) risks (P < 0.001). Multivariate Cox analysis confirmed AJCC stage IV (HR = 2.18, 95% CI: 1.02–4.65), SII ≥ 671.70 (HR = 2.43, 95% CI: 1.42–4.15), and PNI < 46.35 (HR = 3.85, 95% CI: 2.25–6.59) as independent risk factors. A significant synergistic interaction was observed (interaction HR = 1.85, 95% CI: 1.11–3.08, P = 0.018). The nomogram achieved a C-index of 0.861 and an AUC of 0.874 for 3-year OS prediction, outperforming individual markers (P < 0.05). Calibration plots showed excellent agreement, and DCA demonstrated positive net clinical benefit across a wide threshold probability range.
conclusionPretreatment SII and PNI are synergistic and independent prognostic markers for advanced PCa, exhibiting nonlinear relationships with survival outcomes. The developed nomogram provides accurate, individualized survival probability estimation with favorable clinical utility, serving as a practical tool for risk stratification and personalized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.